A Phase III Randomized, Open Label Trial to Evaluate Dolutegravir Versus Efavirenz 400 mg, Both Combined With Tenofovir Disoproxil Fumarate + Lamivudine for the Initial Management of HIV Infected Adults in Resource-limited Settings

Trial Profile

A Phase III Randomized, Open Label Trial to Evaluate Dolutegravir Versus Efavirenz 400 mg, Both Combined With Tenofovir Disoproxil Fumarate + Lamivudine for the Initial Management of HIV Infected Adults in Resource-limited Settings

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Dolutegravir (Primary) ; Lamivudine/tenofovir-disoproxil-fumarate (Primary) ; Efavirenz
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms NAMSAL
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Nov 2016 According to an Unitaid media release, this study is co-financed by UNITAID.
    • 12 Jul 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top